Table IV.
Association between the expression of RP5-919F19 and clinicopathological characteristics of gastric cancer patients.
| Variable | Cases, n (%) | Expression of RP5-919F19 2−ΔΔCq (mean ± standard deviation) | P-value |
|---|---|---|---|
| Gender | 0.672 | ||
| Male | 59 (72) | 4.284±11.597 | |
| Female | 23 (28) | 3.059±9.363 | |
| Age, years | 0.405 | ||
| ≤50 | 30 (37) | 2.446±12.746 | |
| >50 | 52 (63) | 4.617±9.843 | |
| Tumor size, cm | 0.238 | ||
| ≤5 | 43 (52) | 2.434±11.066 | |
| >5 | 39 (48) | 5.404±10.823 | |
| Degree of differentiation | 0.006a | ||
| Well/moderately | 28 (34) | −0.638±6.568 | |
| Poorly | 54 (66) | 6.452±12.135 | |
| TNM stage | 0.015a | ||
| I/II | 44 (54) | 1.170±7.709 | |
| III/IV | 38 (46) | 7.264±13.440 | |
| Lymph node status | 0.029a | ||
| No metastasis | 36 (44) | 0.890±7.236 | |
| Metastasis | 46 (56) | 6.337±12.893 |
a
Statistically significant (P<0.05). TNM, tumor-node-metastasis.